Achieve Life Sciences, Inc. (ACHV)
The price, the headline numbers and the latest news, in one place.
Achieve Life Sciences, Inc. (ACHV) Stock Price, Analysis & Data
| Bid | 7.9 |
| Market Cap | 849M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -114M |
| 2.23 | |
| -1.66 | |
| n/a | |
| -12.96 | |
| P/B (ttm) | -57.69 |
| P/S (ttm) | 0.00 |
| Earnings Date | Nov 5, 2026 |
| Ask | 10.08 |
| Volume | 1,652,180 |
| Avg. Volume (20D) | 1,790,109 |
| Open | 7.83 |
| Previous Close | 7.94 |
| Day's Range | 7.83 - 8.40 |
| 52-Week Range | 2.62 - 8.61 |
| Analyst | Strong<br>Buy |
| Price Target | 12.5 (51.52%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ACHV
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achie...
Financial Performance
In 2025, Achieve Life Sciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -54.65M, an increase of 37.21%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for ACHV stock is "Strong Buy". The 12-month stock price forecast is 12.5, which is upside of 51.52% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -0.8 misses estimates by -0.64, with -116.22% YoY decline.
Analysts project revenue of ... Upgrade
